TY - JOUR
T1 - Bovine colostrum ameliorates diarrhea in infection with diarrheagenic Escherichia coli, Shiga toxin-producing E. coli, and E. coli expressing intimin and hemolysin
AU - Huppertz, Hans Iko
AU - Rutkowski, Stefan
AU - Busch, Dirk H.
AU - Eisebit, Reinhard
AU - Lissner, Reinhard
AU - Karch, Helge
PY - 1999/10
Y1 - 1999/10
N2 - Background: Diarrheagenic Escherichia coli may cause serious extraintestinal complications, but there is no specific treatment. Methods: Patients with diarrhea caused by diarrheagenic E. coli, specifically Shiga toxin-producing E. coli and E. coli-expressing intimin and enterohemorrhagic E. coli-hemolysin were treated by administration of pooled bovine colostrum, rich in antibodies to Shiga toxin and enterohemorrhagic E. coli-hemolysin, in a placebo-controlled, double-blind study. Symptom resolution and fecal excretion of infecting strains were assessed. Results: No side effects were attributable to colostrum. Stool frequencies in the group treated with bovine colostrum were significantly reduced compared with those in the placebo group. No effect of therapy on the carriage of the pathogens or on complications of the infection could be demonstrated. Conclusions: Bovine colostrum is well tolerated and diminishes frequency of loose stools in children with E. coli-associated diarrhea. A prospective study should be conducted among a larger number of children with Shiga toxin-producing E. coli identified early in illness, to determine the effectiveness of colostrum therapy. (C) 1999 Lippincott Williams and Wilkins, Inc.
AB - Background: Diarrheagenic Escherichia coli may cause serious extraintestinal complications, but there is no specific treatment. Methods: Patients with diarrhea caused by diarrheagenic E. coli, specifically Shiga toxin-producing E. coli and E. coli-expressing intimin and enterohemorrhagic E. coli-hemolysin were treated by administration of pooled bovine colostrum, rich in antibodies to Shiga toxin and enterohemorrhagic E. coli-hemolysin, in a placebo-controlled, double-blind study. Symptom resolution and fecal excretion of infecting strains were assessed. Results: No side effects were attributable to colostrum. Stool frequencies in the group treated with bovine colostrum were significantly reduced compared with those in the placebo group. No effect of therapy on the carriage of the pathogens or on complications of the infection could be demonstrated. Conclusions: Bovine colostrum is well tolerated and diminishes frequency of loose stools in children with E. coli-associated diarrhea. A prospective study should be conducted among a larger number of children with Shiga toxin-producing E. coli identified early in illness, to determine the effectiveness of colostrum therapy. (C) 1999 Lippincott Williams and Wilkins, Inc.
KW - Bovine colostrum
KW - Diarrhea
KW - Diarrheagenic Escherichia coli
KW - Hemolytic uremic syndrome
UR - http://www.scopus.com/inward/record.url?scp=0033508212&partnerID=8YFLogxK
U2 - 10.1097/00005176-199910000-00015
DO - 10.1097/00005176-199910000-00015
M3 - Article
C2 - 10512407
AN - SCOPUS:0033508212
SN - 0277-2116
VL - 29
SP - 452
EP - 456
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 4
ER -